Split History
MEIP split history picture
MEI Pharma (MEIP) has 1 split in our MEIP split history database. The split for MEIP took place on December 19, 2012. This was a 1 for 6 reverse split, meaning for each 6 shares of MEIP owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split.

When a company such as MEI Pharma conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the MEIP split history from start to finish, an original position size of 1000 shares would have turned into 166.666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into MEI Pharma shares, starting with a $10,000 purchase of MEIP, presented on a split-history-adjusted basis factoring in the complete MEIP split history. MEIP split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 12/09/2011
End date: 12/07/2021
Start price/share: $6.66
End price/share: $2.70
Dividends collected/share: $0.00
Total return: -59.46%
Average Annual Total Return: -8.63%
Starting investment: $10,000.00
Ending investment: $4,054.42
Years: 10.00
MEI Pharma is a late-stage pharmaceutical company focused on the development and commercialization of cancer therapies. Co.'s drug candidate pipeline includes: Zandelisib, an oral, once-daily, selective phosphatidylinositol 3-kinase delta inhibitor for the treatment of B-cell malignancies; Voruciclib, an orally administered cyclin-dependent kinase inhibitor; ME-344, a tumor selective, isoflavone-derived mitochondrial inhibitor drug candidate; and Pracinostat, an oral histone deacetylase inhibitor being evaluated in patients with high or very high-risk myelodysplastic syndrome who are previously untreated with hypomethylating agents. According to our MEIP split history records, MEI Pharma has had 1 split.
Date Ratio
12/19/20121 for 6
MEIP is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

MELA Split History
MGEN Split History
MLNT Split History
MMM Split History
MMSI Split History
MNKD Split History
MOH Split History
MR Split History
MRK Split History
MRNS Split History

Also explore: MEIP shares outstanding history

Email EnvelopeFree MEIP Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

NAPCO Security Technologies, Inc. (NSSC)
Equitable Group Inc. (EQB.CA)
U.S. Well Services (USWS)
InMode Ltd. (INMD)
Sonim Technologies, Inc. (SONM)
AzurRx BioPharma, Inc. (AZRX)
Jaguar Health, Inc. (JAGX)
Microchip Technology Incorporated (MCHP)
ATIF Holdings Limited (ATIF)
Intuitive (ISRG)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

MEIP Insider Buying

MEIP Split History | www.SplitHistory.com | Copyright © 2013 - 2021, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.